Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy
- First Posted Date
- 2021-08-13
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- AMO Pharma Limited
- Target Recruit Count
- 76
- Registration Number
- NCT05004129
- Locations
- π¨π¦
Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada
π³πΏNew Zealand Clinical Research (NZCR), Auckland, New Zealand
πΊπΈUniversity of California, Los Angeles (UCLA), Los Angeles, California, United States
Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy
- First Posted Date
- 2018-10-02
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- AMO Pharma Limited
- Target Recruit Count
- 56
- Registration Number
- NCT03692312
- Locations
- π¦πΊ
The Bright Alliance, Randwick, New South Wales, Australia
πΊπΈUniversity of Utah Hospital, Salt Lake City, Utah, United States
π³πΏNew Zealand Clinical Research (NZCR), Auckland, New Zealand
Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy
- First Posted Date
- 2016-08-08
- Last Posted Date
- 2018-12-27
- Lead Sponsor
- AMO Pharma Limited
- Target Recruit Count
- 16
- Registration Number
- NCT02858908
- Locations
- π¬π§
Newcastle-upon-Tyne Hospitals NHS Trust, Newcastle Upon Tyne, Tyne And Wear, United Kingdom
Β© Copyright 2025. All Rights Reserved by MedPath